El EPS Q / Q de InVivo Therapeutics Holdings Corp es 39,017.65%
La tasa de crecimiento trimestral del EPS, trimestre a trimestre , es el aumento del EPS de la compañía en los últimos 4 trimestres en comparación con el comportamiento de los 4 trimestres anteriores.
The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi